08-MAR-2026 6:10

LYMPH ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP 1 T 1 CC-486 + R-miniCHOP 422 69 0 0 0 0 0 05/25/2021 198 60
        2 R-miniCHOP   67 1 0 0 0 0      
            136 1 0 0 0 0      
 
  S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 1 Y 0 CD19 CAR T-cell Therapy 396 194 78 41 17 4 1 06/12/2023 134 43
            194 78 41 17 4 1      
 
    2 Y 1 Mosunetuzumab   10 5 1 1 1 0 06/12/2023    
        2 Polatuzumab   11 4 3 1 1 0      
        3 Mosunetuzumab + Polatuzumab   10 4 2 1 0 0      
        4 Observation   10 4 2 0 0 0      
            41 17 8 3 2 0      
 
    3 Y 5 Mosunetuzumab + Polatuzumab   4 3 1 0 0 0 06/12/2023    
            4 3 1 0 0 0      
 
  S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa 1 T 1 Tazemetostat (Arm 1) Dose Level 1 241 7 0 0 0 0 0 09/26/2023 146 40
        10 Tazemetostat (Arm 1) Dose Level 1   6 6 4 0 0 0      
        11 Tazemetostat (Arm 1) Dose Level 2   5 5 5 5 3 0      
        13 Zanubrutinib (Arm 3) Dose Level 2   1 1 1 0 0 0      
        4 Zanubrutinib (Arm 3) Dose Level 1   10 0 0 0 0 0      
        5 Zanubrutinib (Arm 3) Dose Level 2   10 0 0 0 0 0      
            39 12 10 5 3 0      
 
  S2308-FL, LTB, Mosunetuzumab vs Rituximab 1 Y 1 Rituximab 600 135 113 51 24 10 1 10/23/2024 276 90
        2 Mosunetuzumab   134 111 50 23 8 2      
            269 224 101 47 18 3      
 
Yes A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P 1 E Total Registrations   19 5 0 0 0 0 10/14/2023 202 78
            19 5 0 0 0 0      
 
  A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub 1 E Total Registrations   31 15 11 5 3 0 01/03/2024 214 75
            31 15 11 5 3 0      
 
    2 E Total Registrations   14 8 3 2 0 0 01/03/2024    
            14 8 3 2 0 0      
 
  AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy 1 E Total Registrations   90 50 24 10 5 1 08/15/2023 294 127
            90 50 24 10 5 1      
 
    2 E Total Registrations   79 49 20 11 2 0 08/15/2023    
            79 49 20 11 2 0      
 
No EA4232-Lymph, Peri T Cell, Auto Stem 1 E Total Registrations   2 2 2 1 0 0 09/15/2025 44 10
            2 2 2 1 0 0      
 

08-MAR-2026 6:10

LYMPH Recently Closed Studies Accrual Report

OPEN Study Date
Closed		 Reg. Arm Total
Regs		 Regs
Last
30 Days		 Regs
Last
7 Days
T S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa 06-Mar-26 1 1 Tazemetostat (Arm 1) Dose Level 1 7 0 0
        10 Tazemetostat (Arm 1) Dose Level 1 6 0 0
        11 Tazemetostat (Arm 1) Dose Level 2 5 3 0
        13 Zanubrutinib (Arm 3) Dose Level 2 1 0 0
        4 Zanubrutinib (Arm 3) Dose Level 1 10 0 0
        5 Zanubrutinib (Arm 3) Dose Level 2 10 0 0